The current stock price of NYXH is 4.59 USD. In the past month the price decreased by -8.38%. In the past year, price decreased by -56.89%.
ChartMill assigns a fundamental rating of 2 / 10 to NYXH. NYXH has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months NYXH reported a non-GAAP Earnings per Share(EPS) of -2.65. The EPS decreased by -30.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.29% | ||
| ROE | -164.01% | ||
| Debt/Equity | 0.4 |
14 analysts have analysed NYXH and the average price target is 11.05 USD. This implies a price increase of 140.8% is expected in the next year compared to the current price of 4.59.
For the next year, analysts expect an EPS growth of -21.84% and a revenue growth 48.25% for NYXH
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.02 | 188.146B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.95 | 169.625B | ||
| SYK | STRYKER CORP | 23.97 | 137.924B | ||
| BSX | BOSTON SCIENTIFIC CORP | 22.17 | 111.924B | ||
| BDX | BECTON DICKINSON AND CO | 13.75 | 59.33B | ||
| IDXX | IDEXX LABORATORIES INC | 43.44 | 51.339B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.38 | 46.291B | ||
| RMD | RESMED INC | 21.75 | 38.394B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.39 | 37.64B | ||
| DXCM | DEXCOM INC | 27.76 | 27.621B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
NYXOAH SA
Rue Edouard Belin 12
Mont-Saint-Guibert BRABANT-WALLON BE
CEO: Olivier Taelman
Employees: 184
Phone: 3226121755
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
The current stock price of NYXH is 4.59 USD. The price decreased by -1.71% in the last trading session.
NYXH does not pay a dividend.
NYXH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
NYXOAH SA (NYXH) currently has 184 employees.
NYXOAH SA (NYXH) has a market capitalization of 197.51M USD. This makes NYXH a Micro Cap stock.